Which is precisely what we want to know.Eli Lilly's late-stage clinical trial of a monoclonal antibody treatment for COVID-19 has been paused by federal regulators due a safety concern, the company said Tuesday.
[...]
The clinical trial is designed to evaluate Lilly’s neutralizing antibody as a treatment for COVID-19 in hospitalized patients in combination with the antiviral drug remdesivir. It is being tested against a combination of remdesivir and a placebo.
[...]
Thus far, more than 850 trial participants have been dosed, but the company said data from the trial is not yet available.
[...]
The use of antibodies to treat COVID-19 made headlines in the past week after President Trump said he received an antibody cocktail from Regeneron, and touted it as a "miracle" and a "cure."
There's no evidence Regeneron's antibody therapy was responsible for Trump's apparent recovery, and antibodies are not a cure for COVID-19.
Doctors and health experts think antibody drugs could be a bridge to a COVID-19 vaccine but have cautioned that the results to date are very preliminary and that longer studies are needed.
[...]
"Lilly is supportive of the decision by the independent DSMB to cautiously ensure the safety of the patients participating in this study," [spokeswoman Molly McCully told The Hill in an emailed statement.
She did not provide any information about what caused the panel to recommend the pause or how long it might last.
The Hill
...but hey, do what you want...you will anyway.
No comments:
Post a Comment